PFK-015

• Description :

  PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC) [1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy

• Type :

  Reference compound

• Related Pathways :

  Autophagy

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/PFK-015.html

• Purity :

  99.80

• Solubility :

  DMSO : 25.2 mg/mL (ultrasonic; warming)

• Smiles :

  O=C(C1=CC=NC=C1)/C=C/C2=NC3=CC=CC=C3C=C2

• Molecular Formula :

  C17H12N2O

• Molecular Weight :

  260.29

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Jia Bo Zheng, et al. Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. Oncoimmunology. 2022 May 25;11 (1) :2079182. |[2]Brian Clem, et al. Characterization of a novel small molecule antagonist of 6-phosphofructo-2-kinase that suppresses glucose metabolism and tumor growth. ORAL PRESENTATIONS - PROFFERED ABSTRACTS| APRIL 15 2011.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [4382-63-2]